Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00521079




Registration number
NCT00521079
Ethics application status
Date submitted
23/08/2007
Date registered
27/08/2007
Date last updated
24/08/2018

Titles & IDs
Public title
EMPOWER Clinical Trial: Vagal Blocking for Obesity Control
Scientific title
EMPOWER Clinical Trial: Vagal Blocking for Obesity Control
Secondary ID [1] 0 0
D00343-000
Universal Trial Number (UTN)
Trial acronym
EMPOWER
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Obesity 0 0
Condition category
Condition code
Diet and Nutrition 0 0 0 0
Obesity
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Therapy ON
Treatment: Devices - Therapy OFF

Experimental: vBloc - Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).

Sham Comparator: Placebo - Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).


Treatment: Devices: Therapy ON
Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)

Treatment: Devices: Therapy OFF
Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)

Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Excess Weight Loss (EWL) With the Maestro System - Observe at least a 10% greater percentage excess weight loss (%EWL) with vBloc therapy delivered by the Maestro System compared to sham 12 months following randomization using MetLife Method (ideal body weight is calculated based on Metropolitan Height and Weight Tables)
Timepoint [1] 0 0
Baseline and 1 Year
Primary outcome [2] 0 0
Rate of System and Procedure-related Serious Adverse Events (SAEs). - To estimate the rate of serious, system- and procedure-related adverse events associated with the Maestro System.
Timepoint [2] 0 0
1 Year
Secondary outcome [1] 0 0
Percentage of Participants Achieving 25% Excess Weight Loss (%EWL) - To evaluate the percentage of participants achieving 25% excess weight loss from baseline (implant) to 12 months between treatment groups.
Timepoint [1] 0 0
Baseline and 1 Year

Eligibility
Key inclusion criteria
Inclusion criteria

1. Informed consent.

2. Body mass index (BMI) = 40 kg/m2 to 45 kg/m2 or BMI = 35 kg/m2 to 39.9 kg/m2 with one
or more obesity related co-morbid condition. Co-morbid conditions may include one or
more of the following:

- Type 2 diabetes mellitus (note: type 2 diabetics are allowed at selected centers
only, see Inclusion criterion #5)

- Hypertension as defined by systolic pressure =140 mmHg and/or diastolic pressure
=90 mmHg a) treated or untreated with systolic =140 mmHg or diastolic =90 mmHg or
b) treated with systolic <140 mmHg and diastolic <90 mmHg

- Dyslipidemia as defined by total cholesterol =200 or LDL =130 a) treated or
untreated with total cholesterol =200 or LDL =130 or b) treated with total
cholesterol <200 or LDL <130

- Sleep apnea syndrome (confirmed by overnight p02 studies)

- Obesity related cardiomyopathy

3. Females or males Note: females of child-bearing potential must have a negative urine
pregnancy test at Screen and also within 14 days of implant procedure followed by
physician-approved contraceptive regimen for the duration of the study period.

4. 18-65 years of age inclusive.

5. Type 2 diabetes mellitus subjects (at selected centers, limited to approximately 34
subjects) with:

- Glycosylated hemoglobin (Hb A1c) 6.5 - 9 % inclusive at screening visit.

- Onset: 10 years or less since initial diagnosis.

- Stable treatment regimen: no change in oral hypoglycemic treatment regimen within
past 3 months.

- Currently not using insulin therapy, GLP-1 receptor agonists (e.g., exenatide),
or DPP-4 inhibitors (e.g., sitagliptin) for diabetes treatment and have not been
on these treatments in the past 6 months.

- Creatinine within normal reference range.

- No history of proliferative retinopathy.

- No history of peripheral neuropathy.

- No history of autonomic neuropathy.

- No history of coronary artery disease, with or without angina pectoris.

- No history of peripheral vascular disease.

6. Failure to respond to supervised diet/exercise program(s) in which the subject was
engaged for at least 6 months within the last five years.

7. Ability to complete all study visits and procedures.
Minimum age
18 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria

1. Concurrent chronic pancreatic disease.

2. History of Crohn's disease and/or ulcerative colitis.

3. History of bariatric surgery, fundoplication, gastric resection or major
upper-abdominal surgery (acceptable surgeries include cholecystectomy, hysterectomy).

4. History of pulmonary embolism or blood coagulation disorders.

5. Clinically significant hiatal hernias known from subject's medical record as or
determined by upper endoscopy prior to implant if they have not had one done during
the previous 6 months that specifically reported on the presence or absence of hiatal
hernia making reference to the Z-line and/or diaphragmatic notch, in order to rule out
subjects with hiatal hernia that may require surgical repair (to support exclusion
criterion #7).

6. Current portal hypertension and/or esophageal varices.

7. Intra-operative exclusion: hiatal hernia requiring surgical repair or extensive
dissection at esophagogastric junction at time of surgery.

8. Treatment with weight-loss prescription drug therapy within the prior three months and
the use of prescription drug therapy or the use over-the-counter weight loss
preparations for the duration of the trial.

9. Smoking cessation within the prior six months.

10. Known genetic cause of obesity (e.g., Prader-Willi Syndrome).

11. Overall sustained reduction of more than 10% of body weight in the previous 12 months.

12. Physician-prescribed pre-operative diet with intent to lose weight prior to surgery
(note: a) study subject may continue any personal diet they were on prior to study
enrollment [see exclusion criterion #24] b) standardized EMPOWER weight management
program to be initiated in all subjects at time of activation, approximately two weeks
after implant)

13. Current type 1 diabetes mellitus (DM).

14. Current or recent history (within 12 months) of ongoing bulimia.

15. Current alterations in treatment for thyroid disorders (stable treatment regimen for
prior three months acceptable).

16. Current alterations in treatment for epilepsy (stable treatment regimen for prior six
months acceptable).

17. Current treatment for peptic ulcer disease (previous history acceptable).

18. Chronic (more than 4 weeks of daily use) treatment with narcotic analgesic drug
regimens (treatment with non-steroidal anti-inflammatory drugs acceptable).

19. Current alterations in treatment regimens of anti-cholinergic drugs, including
tricyclic antidepressants (stable treatment regimen for prior six months acceptable).

20. Current medical condition that, in the opinion of the investigator, would make subject
unfit for surgery under general anesthesia or that would be exacerbated by intentional
weight loss. Some examples include diagnosis of cancer, recent heart attack, recent
stroke or recent serious trauma.

21. Presence of permanently implanted electrical powered medical device or implanted
gastrointestinal device or prosthesis (e.g., pacemakers, implanted defibrillators,
neurostimulators etc.).

22. Planned or contemplated use of Magnetic Resonance Imaging (MRI) or oncological
radiation during the course of the trial.

23. Significant psychiatric disorders that, in the opinion of the investigator, may
interfere with subject's ability to follow study procedures and/or instructions.

24. Current, active member of an organized weight loss program (e.g., Weight Watchers,
TOPS).

25. Current participant in another weight loss study or other clinical trials.

26. Have a friend or family member who is currently participating or is planning to
participate in this clinical trial.

27. Patient reported:

- inability to walk for about 10 minutes without stopping,

- feeling of pain in chest when doing physical activity,

- feeling of pain in chest when not doing physical activity. Note: unless pain in
chest in known to be related to upper gastrointestinal disorders such as
gastroesophageal reflux disease or heartburn.

28. Clinically significant cardiac rhythm disorder that requires either medical and/or
surgical intervention (e.g., paroxysmal or chronic atrial fibrillation).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
Institute of Weight Control - Sydney
Recruitment hospital [2] 0 0
Adelaide Bariatric Center - Flinders Private Hospital - Bedford Park
Recruitment postcode(s) [1] 0 0
2153 - Sydney
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Maryland
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
Virginia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ReShape Lifesciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized multi-center study being done to measure the ability of a new medical
device, Maestro System, to safely reduce body weight over five years in people who are
considered obese.
Trial website
https://clinicaltrials.gov/show/NCT00521079
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Charles J Billington, MD
Address 0 0
VA Medical Center, Minneapolis, MN / University of Minnesota
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications